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With the advent of new antiepileptic drugs comes the potential for significant advances
in the emergent management of status epilepticus.Traditional antiepileptic drugs possess
side effect profiles that may limit their clinical utility or lead to increased patient morbidity
or mortality. The relatively recent development of levetiracetam shows promise for effec-
tive control of acute status epilepticus in adults, but current objective data of its use as
a first-line agent for control of status is quite limited. This paper serves to examine exist-
ing literature while considering levetiracetam as a first-line therapy in status in the adult
patient population. Although existing studies are narrow in their scope, the present data
lay a substantial foundation for further investigation of levetiracetam as a primary therapy
in acute status epilepticus.
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INTRODUCTION
The emergent management of status epilepticus has been
restricted to a small subset of antiepileptic drugs suitable for acute
intravenous infusion. Of the three major traditional drugs used in
first-line therapy for status, each carries a side effect profile that
may ultimately lend to limited clinical utility in the critical patient.
Lorazepam, phenytoin, and phenobarbital individually convey
specific risks to the patient, among them respiratory depression,
medication interaction due to cyp450 induction, and teratogenic-
ity (1). Each of these known effects may complicate their use in an
urgent setting and contribute to increased morbidity in patients
presenting with status epilepticus (1).
Given its minimal known side effect profile, limited drug
interactions, and availability as a rapid delivery IV formulation,
levetiracetam, a relatively new AED by comparison, may be a
viable, and practical option in the first-line management of sta-
tus epilepticus (2, 3). Status epilepticus has been defined most
commonly as seizure activity persisting for over 30 min, inclu-
sive of tonic, absence, complex partial, convulsive, non-convulsive,
and myoclonic seizure types, among others. The majority of data
regarding the use of levetiracetam in status epilepticus has been
applied to generalized seizure types, though there is growing
interest in its application for a variety of epileptic activity (4).
TRADITIONAL AND EMERGING MANAGEMENT OF STATUS
EPILEPTICUS
The traditional approach taken in the emergent management of
status was described by Riviello et al. (5) in their survey of 120
physicians who were asked to manage hypothetical patients diag-
nosed with status epilepticus (5). When given the case of an adult
male without a known underlying seizure disorder, the physician
subjects overwhelmingly initiated benzodiazepine therapy first,
choosing lorazepam followed by phenytoin as a secondary agent
(5). Levetiracetam was not chosen until the physician was required
to select a third agent, with it being selected with the same fre-
quency as midazolam, propofol, or phenobarbital (5). Cook et
al. (6) echoed this sentiment with a 150 patient retrospective
study, again noting that in real clinical applications, physicians
readily followed the first-line benzodiazepine trailed by pheny-
toin model (6). Although levetiracetam was not chosen until the
patient required a third-line agent, Cook et al. (6) did note that
10% of patients received levetiracetam as a second-line agent in
their evaluations (6). Additionally, levetiracetam was the second
most-selected third-line agent. The authors postulate that this may
be indicative of growing acceptance of levetiracetam as a promis-
ing therapy in status (6). Cook et al. (6) did call attention to 65.1%
of patients in the study continuing levetiracetam therapy upon
discharge home with a particular frequency in patients with no
prior history of seizure (6). Taken together, this is suggestive of a
slowly developing physician comfort with levetiracetam.
The reasoning behind the traditional management of status
is perhaps most apparent in Brophy et al.’s (7) discussion of the
Neurocritical Care Society’s Status Epilepticus Guideline Writing
Committee, which set forth parameters for a stepwise approach
to the management of status epilepticus (7). This initial set of
standards favored benzodiazepine therapy as a first-line modal-
ity citing the utility of the multiple administration routes and
rapid infusion times common to many benzodiazepines, most
notably lorazepam, and midazolam (7). The guidelines do offer
the caveat of respiratory depression with benzodiazepine ther-
apy with the potential need for intubation with repeated dosing
(7). While the committee limited their recommendations for the
emergent control of status epilepticus to benzodiazepines, leve-
tiracetam was given a strong recommendation for urgent control
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of status along with two other drugs, valproate sodium and pheny-
toin/fosphenytoin (7). Of these drugs, however, levetiracetam is
the only agent not noted in the guidelines for having a serious
potential side effect profile (7). Although levetiracetam currently
is listed as having only Class IIA, Level C evidence supporting its
use in emergent, urgent, and refractory status, its adoption as a
strongly recommended therapy for urgent status epilepticus pro-
vides for reasonable interpretation that an expansion of available
clinical evidence could lead to its eventual acceptance as a first-line
therapy in the emergent management of status (7).
LEVETIRACETAM AS A FIRST-LINE AGENT
While levetiracetam is approved as an adjuvant agent for the man-
agement of status, data on its use as a first-line therapy is quite
limited, as noted in the Neurocritical Care Society’s Guidelines
discussed previously. Review of available literature via PubMed
search reveals fewer than 10 reports of levetiracetam used as a
first-line agent in status, with only a single randomized pilot study
and a limited number of case and retrospective reports available
in current publication. Despite this, evaluating existing data as a
whole opens the discussion for levetiracetam administration as a
first-line approach in status epilepticus.
A clinical pilot performed by Misra et al. (8) provides the
only direct comparison of levetiracetam and a traditional first-
line agent, lorazepam, in available literature (8). A loading dose
of lorazepam or levetiracetam was administered to each of 79
patients between the ages of 1 and 75 with convulsive or subtle
convulsive status epilepticus (defined as two or more seizures) (8).
While pediatric patients were included in the study, no formal
breakdown of the age distribution of the patient population was
included in the study report. It should be noted that the mean age
of subjects receiving lorazepam was 38.9 years with a mean age of
39.2 for patients receiving levetiracetam. Levetiracetam infusion
controlled status in 76.3% of patients with lorazepam achieving
the same in 75.6% (8). Slightly improved 24-h seizure freedom
was noted in patients in the levetiracetam group (8). Interestingly,
there was more frequent need for artificial ventilation in patients
receiving first-line lorazepam, though no significant difference
in mortality between the two groups was ultimately illustrated
(8). While this pilot was hindered by limited power due to sub-
ject recruiting, it stands as the only available direct comparison
between a traditional first-line agent and levetiracetam (8).
In a review written by Zelano and Kumlien (9), levetiracetam
was evaluated as a stage two therapy in status management in an
analysis of 10 studies (9). The review included three prospective
and seven retrospective studies, which comprised total 334 patients
(9). Ultimately, the studies represented an efficacy range for leve-
tiracetam of 44–94% (9). The authors’ work further substantiates
the notion of levetiracetam as an effective clinical option with
applications to a broader range of patients, not just those with-
out potential drug interactions, feared toxicity, or other foreseen
adverse reactions to traditional therapies.
UTILITY IN PHARMACOLOGY AND TOLERABILITY
Levetiracetam’s limited side effect profile makes it particularly
appealing in older patient populations, where drug interaction and
the potential for intubation leading to significant mortality is of
great concern. Fattouch et al. explored this in a limited retrospec-
tive of nine patients, older than 65 years old with video EEG con-
firmed status epilepticus who received loading doses of 1500 mg
IV levetiracetam as a first-line agent (10). Eight of nine cases
responded to loading dose within 15–30 min of dosing with con-
firmation obtained via EEG, with only one of whom experienced
a few isolated seizures in the days following dosing (10).
Additionally, Farooq et al. (11) reported two cases of patients,
older than 80 years old who responded within 35 min to leve-
tiracetam load (11). This limited report features the cases of a
patient already receiving daily levetiracetam therapy who had
missed a dose and another patient found to be therapeutic on
phenytoin whose seizures ceased within a minute of levetiracetam
administration (11).
Berning et al. (12) addressed the issue of first-line levetiracetam
in patients in whom there was a high level of concern for the risks
of coma induction and subsequent increased mortality (12). The
group reported on 2 patients out of a larger group of 32 individuals
in status who were treated exclusively with levetiracetam within 6 h
of seizure onset and who responded to therapy between 6 and 18 h
after administration of the agent and required no further therapy
(12). Berning et al. (12) also incorporated patients categorized as
“low first line therapy,” specifically eight patients treated with low
dose (2 mg) lorazepam or equivalent prior to administration of
levetiracetam in lieu of “high first line” or “traditional first line
therapies” (12). In this case, the patients who received either no
traditional first-line drugs or only low dose benzodiazepines had
lower change in morbidity when compared to more aggressive
traditional first-line interventions (12).
LEVETIRACETAM IN THE CRITICALLY ILL
It is the potential for limited increase in mortality that makes lev-
etiracetam particularly appealing for first-line use in critically ill
patients, which was explored by Rüegg et al. (13). In their analysis,
12 patients received first-line levetiracetam for status epilepticus
or seizure as part of a larger 50 patient study (13). Eleven of 12
patients became and remained seizure free after load with 4 of
those patients becoming seizure free immediately after adminis-
tration, with confirmation obtained via EEG (13). Importantly,
the group described the need for a therapeutic ideal with prop-
erties of ability for rapid dosing with instantaneous onset and
minimal toxicity, sedation, and interaction with the hypothesis
that levetiracetam best fits such a description among commercially
available AEDs (13).
Spencer et al. (14) pointed out the benefit of levetiracetam
reaching peak steady state concentrations within an hour of
administration; though with the caution that it has demonstrated
a more rapid administration rate in a small subset of critically
ill patients (14). Lyseng-Williamson (15) also described the clini-
cal tolerability of levetiracetam, noting in her review that adverse
effects of major concern in a critically ill patient, such as hypoten-
sion, arrhythmias, and cutaneous and hypersensitivity reactions,
were not commonalities in the use of levetiracetam in its initial
clinical trials (15). Instead, asthenia and somnolence were noted
among its major side effects (15).
Nau et al. (16) served to further this data with a retrospec-
tive analysis of 51 patients, 18 of whom received a loading dose
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of 1500 mg levetiracetam. Seventeen of those 18 patients received
levetiracetam as first-line monotherapy (16). Of these patients, no
drug interactions, cardiac arrhythmias, or adverse hemodynamic
events were recorded, similarly suggesting that levetiracetam has
the potential to be well tolerated in the critically ill (16). In the
same vein, Rösche et al. (17) provided a comprehensive review of
literature concerning the treatment of status epilepticus with leve-
tiracetam, though not specifically as a first-line agent. The authors
found an on-the-whole rate of levetiracetam terminating status
in 53.7–58.1% of patients with the most frequent side effects of
irritability and sedation (17).
PRACTICAL APPLICATIONS IN THE CURRENT THERAPEUTIC
SEQUENCE
Liu et al. (18) served to further this concept with a literature
based comparison of intravenous valproate sodium with other
antiepileptic drugs by completing meta-analysis performed on
five randomized control trials (18). No substantial difference was
noted between valproate sodium and levetiracetam in time taken
to control status, and similar responses for phenytoin and sodium
valproate were found. These are suggestive of similar efficacies of
all three agents (18). Of the three, however, the relatively benign
side effect profile of levetiracetam makes it an appealing choice of
agent given the agents’ equivalent drug efficacies.
Aiguabella et al. (19) set out to determine the efficacy of intra-
venous levetiracetam as an add-on agent in the management of
status in their observational retrospective study of 40 patients.
These patients received initially the traditional regimen of a ben-
zodiazepine followed by phenytoin or valproate (19). Ultimately,
seizures were controlled in 57.7% of patients with a mean efficacy
time of 14.4 h (19). Of the 40 patients, only 26 ultimately received
the traditional regimen followed by levetiracetam given as a third-
line agent. Those patients have a levetiracetam efficacy of only
46.1%. Interestingly,when levetiracetam was given early,with min-
imal or no pretreatment,as was done in the cases of 14 subjects, lev-
etiracetam was found to have an efficacy of 78.5% (19). Ultimately,
the authors postulate that the higher efficacy of levetiracetam early
in therapy may be attributed to the idea that status epilepticus
requiring multiple agents to reach control were likely to be more
treatment refractory from the outset (19). That being said, Aigua-
bella et al.’s (19) work raises the notion that while other agents
may also readily control status as an early therapy, levetiracetam
may do so with at least equal efficacy with less morbidity.
DISCUSSION
While clinical studies of the use of levetiracetam are undoubtedly
not yet sufficient to dictate large-scale changes to clinical practice, a
substantial foundation for future clinical trials has been laid. Given
multiple case reports of successful use of levetiracetam as an initial
agent in the emergent treatment of status, there is certainly basis
for the development of larger scale randomized controlled trials
allowing for a direct, standardized comparison between traditional
first-line agents and levetiracetam for emergent management of
status epilepticus. The clinical utility of levetiracetam is most sug-
gested by Misra et al.’s (8) pilot study as well as retrospective
analyses of the use of levetiracetam in critically ill patients with
seizures and status (8). Perhaps the greatest potential advantages
to levetiracetam are its pharmacologic properties and restricted
morbidity via minimal side effect and interaction profiles. Studies
indicate that levetiracetam is an attractive option in patients who
are unable to be treated with traditional first-line therapies. This
may serve as a catalyst for the exploration of levetiracetam as a
first-line medication. Although existing clinical evidence is inade-
quate, the recommendations of the Neurocritical Care Society for
the management of status show a potential for an expanding role
of levetiracetam in the management of status with its inclusion of
recommended drugs that may be selected in the urgent manage-
ment of status. In the same way, Cook et al. (6) foreshadow a shift
in the traditional line of medical decision making in status with
a small but not insignificant number of physicians choosing leve-
tiracetam early on in the management of status (6). While a jump
as extensive as levetiracetam approaching recognition as a first-line
agent is still far beyond what current models and data support, the
basis for more in-depth studies for its potential to function specif-
ically as a first-line agent is formed with considerable feasibility by
these underlying works.
Such a hypothesis exists that levetiracetam may well fit the
description of an ideal agent as outlined by Reugg et al. (13).
Lyseng and Spencer further support this notion of levetiracetam
as a readily administered and rapidly absorbed drug with low fre-
quency of high-risk adverse effects, and in fact, a benign side effect
profile when compared directly to other traditional agents (14,
15). This then portends the argument that levetiracetam could
1 day usurp traditional antiepileptic agents in order of administra-
tion in status given the rapidity of its administration, absorption,
efficacy noted as an early therapy, and minimal side effect pro-
file. Perhaps, it is worthy of first-line administration, ahead of
traditional agents. Accomplishing this cannot be done without
further endeavors, however. No current randomized controlled
clinical trial of levetiracetam used in the management of acute
adult status epilepticus currently exists, though the potential yield
is substantial. Aiguabella et al. (19) create an interesting scenario
in their brief observation that difficult-to-control status is fun-
damentally what it purports to be challenging to manage (19).
For example, a patient whose seizures prove complex to control
will likely require multiple agents with repeated dosing in order
to successfully stop the seizures. However, a patient with readily
responsive seizures may respond initially to levetiracetam as well
as traditional antiepileptic drugs, albeit with less risk of interac-
tions, and side effects. It is worth questioning if adverse effects
experienced in patients whose seizures ultimately responded to
traditional first-line therapy but then experienced complications
or side effects such as respiratory depression, could be avoided by
a better-tolerated therapy, namely levetiracetam. In this manner, a
wider range of patients could be potentially treated earlier, more
safely, and just as effectively as with mainline drugs used in status.
Certainly no pharmacotherapy is without fault, and it remains
both possible and likely that levetiracetam carries administra-
tion concerns not yet apparent to clinical practitioners. Just as
our understanding of its clinical benefits are restricted by limited
data, so too is our comprehension of its potential pitfalls. With
the growing establishment of levetiracetam’s clinical pedigree, as
well as ever-increasing desire for an efficacious, accessible, and
comparatively benign agent for the emergent treatment of status,
levetiracetam may prove a worthy contender in the future of acute
treatment of status epilepticus.
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